Harbor Branch Oceanographic Institution, Inc.

Florida Atlantic University

Ross E Longley

Shirley A Pomponi

Amy E Wright

Sarath P Gunasekera

Peter J McCarthy

Richard A Isbrucker

John K Reed

Neal S Burres

Frank Koehn

Ying Hai Chen

Oliver J McConnell

Malika Gunasekera

Nanda K Gulavita

Jennifer L Cummins

Gopal K Paul

Paul A Horton

Gabriel G Saucy

Glynn Thomas Faircloth

Sue S Cross

Steve Coval

Ranjit C Desai

Srinivasa Reddy Natala

Geewananda P Gunawardana

Richard D Wood

Jill Roberts

K Brian Killday

Sarath P Gunaskera

The subject invention provides novel biologically active compounds that have utility for use in inhibiting cellular proliferation. Pharmaceutical compositions comprising these compounds are also provided. In a specific embodiment, the compounds and compositions of the subject invention can be used in the treatment of cancer.

Antiproliferative activity of the leiodermatolide class of macrolides

The subject invention provides novel compositions of biologically active macrolide compounds which can advantageously be used in blocking cellular proliferation, treatment of cancer, treatment of fungal infections and control of spoilage of food, cosmetic and other consumer items.

Biologically active lasonolide compounds

The subject invention provides novel compositions of biologically active polyketide compounds that can advantageously be used in blocking cellular proliferation and treatment of cancer.

Biologically active raspailamide compounds

The subject invention provides novel compositions of biologically active compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.

Lactone compounds and methods of use

The subject invention provides novel compositions of biologically active linderazulene terpene compounds which can advantageously be used for treating cancer and stopping cell proliferation.

Biologically active linderazulene terpenes

The subject invention provides novel compositions of biologically active discorhabdin compounds which can advantageously be used for inhibiting pathological cellular proliferation. The compounds of the subject invention have utility for use in the treatment of cancer, including tumors.

Discorhabdin compounds and methods of use

The subject invention provides novel compositions of biologically active glycosylated pregnene compounds which can advantageously be used for treating cancer and stopping cell proliferation.

Biologically active pregnene compounds

Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.

Compositions and uses of dictyostatin compounds

The subject invention provides novel compositions of biologically active discodermolide compounds which can advantageously be used for immunomodulation and/or treating cancer. The compounds of the subject invention have utility for use in the treatment of cancer, as tubulin polymerizers and as microtubule stabilization agents. The present invention also pertains to the identification of regions of the discodermolide molecule which are responsible for certain aspects of the bioactivity of discodermolide compounds.

Biologically active analogs of discodermolide

The subject invention provides novel biologically active compounds which are useful for inhibiting cellular proliferation. Because of the biological activity of these compounds, they can be used for immunomodulation and/or treating cancer. In a preferred embodiment, the novel compounds, compositions and methods of use of the subject invention can advantageously be used to inhibit the growth of tumor cells in a mammalian host. More particularly, the subject compounds can be used for inhibiting in a human the growth of tumor cells, including cells of breast, colon, CNS, ovarian, renal, prostate, bone, gastrointestinal, stomach, testicular, or lung tumors, as well as human leukemia or melanoma cells. Specifically exemplified are discalamides A and B.

Discalamide compounds and their use as anti-proliferative agents

The subject invention pertains to a series of cyclic peptides known as the microsclerodermins, which possess unusual amino acids, and which have been observed to inhibit the proliferation of tumor cell lines. The subject invention also pertains to methods useful in inhibiting pathological cellular proliferation in animals, including humans and other mammals. In accordance with the teachings of the subject invention, microsclerodermin compounds can be used to inhibit cellular proliferation including that which is responsible for tumors and other cancers. In a specific embodiment, the novel compositions and methods of use of the subject invention can advantageously be useful in the treatment of a patient hosting cancer cells, for example, inhibiting the growth of tumor cells in a mammalian host.

Antiproliferative activity of microsclerodermins

The subject application concerns novel compounds with useful biological properties. For example, these compounds can be used as antinflammatory, anti-proliferative, immunomodulatory, and/or neuroprotective agents. Specific examples of the compounds of the subject invention include Secobatzelline A and Secobatzelline B, which can be isolated from marine sponges.

Aminoiminoquinone and aminoquinone alkaloid compounds and methods of use

Novel analogs of compounds from the marine sponge Discodermia dissoluta have been prepared. These compounds have been shown to have activity against mammalian cancer cells, and can be used in treating human patients which host cancer cells, including leukemia, melanoma, breast, colon, CNS, renal, ovarian, prostate, and lung tumors.

Growing community of inventors

Tallahassee, FL, United States of America

Ross E Longley